In Vitro Activity of Sch 21420, Derivative of Gentamicin B, Compared to That of Amikacin
AUTOR(ES)
Kabins, Sherwin A.
RESUMO
The minimal inhibitory concentration of Sch-21420 closely paralleled amikacin for 125 strains of aerobic gram-negative bacilli and Staphylococcus aureus primarily selected for testing because of resistance to other aminoglycoside antibiotics. Fifteen of 26 strains requiring 20 μg or more of amikacin per ml for inhibition were inhibited by two- to fourfold less Sch 21420. The majority of organisms resistant to both agents owed their resistance to mechanisms other than the carriage of aminoglycoside-modifying enzymes. Most strains carrying aminoglycoside 6′-acetyltransferase, capable of modifying amikacin, were susceptible to 10 μg or less of Sch 21420 per ml.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=352551Documentos Relacionados
- Comparison of in vitro activity of Sch 21420, a gentamicin B derivative, with those of amikacin, gentamicin, netilmicin, sisomicin, and tobramycin.
- In Vitro Evaluation of a Semisynthetic Derivative of Gentamicin B (SCH 21420)
- Comparative nephrotoxicity of SCH 21420 and amikacin in rats.
- In Vitro Activity of Netilmicin Compared with Gentamicin, Tobramycin, Amikacin, and Kanamycin
- Interpretive standards for disk susceptibility tests with Sch 21420 and amikacin.
